ATE115588T1 - Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist. - Google Patents

Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist.

Info

Publication number
ATE115588T1
ATE115588T1 AT87200461T AT87200461T ATE115588T1 AT E115588 T1 ATE115588 T1 AT E115588T1 AT 87200461 T AT87200461 T AT 87200461T AT 87200461 T AT87200461 T AT 87200461T AT E115588 T1 ATE115588 T1 AT E115588T1
Authority
AT
Austria
Prior art keywords
producing
determining
antibody capable
human oncogene
oncogene
Prior art date
Application number
AT87200461T
Other languages
English (en)
Inventor
Robert A Weinberg
Clifford James Tabin
Scott M Bradley
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE115588T1 publication Critical patent/ATE115588T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT87200461T 1982-10-01 1983-09-29 Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist. ATE115588T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/432,337 US4535058A (en) 1982-10-01 1982-10-01 Characterization of oncogenes and assays based thereon

Publications (1)

Publication Number Publication Date
ATE115588T1 true ATE115588T1 (de) 1994-12-15

Family

ID=23715723

Family Applications (3)

Application Number Title Priority Date Filing Date
AT87200460T ATE114820T1 (de) 1982-10-01 1983-09-29 Verfahren zur bestimmung von durch onkogene verursachten krebs.
AT87200461T ATE115588T1 (de) 1982-10-01 1983-09-29 Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist.
AT83903635T ATE59412T1 (de) 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT87200460T ATE114820T1 (de) 1982-10-01 1983-09-29 Verfahren zur bestimmung von durch onkogene verursachten krebs.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT83903635T ATE59412T1 (de) 1982-10-01 1983-09-29 Charakterisierung von onkogenen und darauf beruhende bestimmungen.

Country Status (6)

Country Link
US (3) US4535058A (de)
EP (4) EP0120958B1 (de)
JP (2) JPH0642840B2 (de)
AT (3) ATE114820T1 (de)
DE (3) DE3382767T2 (de)
WO (1) WO1984001389A1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713619B1 (en) * 1980-08-29 2004-03-30 Massachusetts Institute Of Technology Oncogenes and methods for their detection
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
USRE35491E (en) * 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) * 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US5733738A (en) * 1983-08-17 1998-03-31 Ligand Pharmaceuticals Polypeptide-induced monoclonal receptors to protein ligands
US5030565A (en) * 1983-08-17 1991-07-09 Scripps Clinic And Research Foundation Polypeptide-induced monoclonal receptors to protein ligands
US5591587A (en) * 1983-08-17 1997-01-07 The Scripps Research Institute Polypeptide-induced monoclonal receptors to protein ligands
US4681840A (en) * 1984-01-18 1987-07-21 The United States Of America As Represented By The Secretary Of Commerce Deoxyribonucleic acid molecules useful as probes for detecting oncogenes incorporated into chromosomal DNA
US4725550A (en) * 1984-01-19 1988-02-16 Research Foundation Of State University Of New York Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US5087571A (en) * 1984-06-22 1992-02-11 President And Fellows Of Harvard College Method for providing a cell culture from a transgenic non-human mammal
US4866166A (en) * 1984-08-31 1989-09-12 Cold Spring Harbor Laboratory Bioassay for transforming genes and genes detected thereby
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
EP0177814A3 (de) * 1984-09-19 1987-12-02 Cetus Corporation Antikörper gegen Peptide und ihre Verwendung zum Nachweis von Onkogene-Produkten
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4701409A (en) * 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4735895A (en) * 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US5028527A (en) * 1988-02-22 1991-07-02 Applied Bio Technology Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
US6200764B1 (en) 1985-01-29 2001-03-13 Bayer Corporation Detection, quantitation and classification of ras proteins in body fluids and tissues
US5081230A (en) * 1987-07-08 1992-01-14 E. I. Dupont Denemours And Company Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
CA1296660C (en) * 1985-01-29 1992-03-03 Walter P. Carney Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US4898932A (en) * 1985-01-29 1990-02-06 E. I. Du Pont De Nemours And Company Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5443956A (en) * 1985-01-29 1995-08-22 Oncogene Science, Inc. Detection, quantitation and classification of RAS proteins in body fluids and tissues
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
FR2589882B2 (fr) * 1985-11-13 1988-01-15 Pasteur Institut Moyens pour le diagnostic in vitro de cellules malignes originaires du tube digestif
US5635389A (en) * 1985-05-02 1997-06-03 Institut Pasteur Antibodies which recognize and bind human villin
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US6083709A (en) * 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
US4946773A (en) * 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US5320941A (en) * 1986-06-06 1994-06-14 Dallan Young DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US4820631A (en) * 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
US5853988A (en) * 1986-08-11 1998-12-29 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US7223842B1 (en) 1986-08-11 2007-05-29 Massachusetts Eye And Ear Infirmary Detection of proteins whose absence is associated with a neoplasm
US7384735B1 (en) 1986-08-11 2008-06-10 Massachusetts Eye And Ear Infirmary Retinoblastoma nucleic acids
CA1341576C (en) * 1986-08-11 2008-07-08 Thaddeus P. Dryja Diagnosis of retinoblastoma
EP0262942A1 (de) * 1986-09-30 1988-04-06 Smithkline Beecham Corporation Zelltransfektion
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5789235A (en) * 1987-03-23 1998-08-04 Tackett; Scott E. Modifying cell metabolism via extra-cellular nucleases
US4870161A (en) * 1987-09-25 1989-09-26 The United States Of America As Represented By The Department Of Health And Human Services Reagents and probes for distinguishing and isolating different GTP-binding proteins
CA1339069C (en) * 1987-11-09 1997-07-29 Henry Lee Niman Polypeptide-induced monoclonal receptors to protein ligand
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
US5112737A (en) * 1988-02-22 1992-05-12 Applied Biotechnology, Inc. Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
DE3809635C3 (de) * 1988-03-22 1996-06-20 Niehoff Kg Maschf Verfahren und Vorrichtung zur Herstellung eines spulenlosen Gebindes sowie ein mit dem Verfahren hergestelltes Gebinde
DE68929511T2 (de) * 1988-04-22 2004-11-18 Bayer Corp. Nachweis, Quantifizierung und Klassifizierung von RAS-Proteinen in Körperflüssigkeiten und Geweben
WO1989012697A1 (en) * 1988-06-22 1989-12-28 The Board Of Regents Of The University Of Washingt Method for detecting abnormal genes
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
FR2645877B1 (fr) * 1989-04-12 1991-07-05 Pasteur Institut Molecules comportant au moins une sequence peptidique porteuse d'un, ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum au niveau du stade sporozoite et dans les hepatocytes
AU660405B2 (en) * 1989-07-18 1995-06-29 Osi Pharmaceuticals, Inc. Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US6203976B1 (en) * 1989-07-18 2001-03-20 Osi Pharmaceuticals, Inc. Methods of preparing compositions comprising chemicals capable of transcriptional modulation
US5776502A (en) 1989-07-18 1998-07-07 Oncogene Science, Inc. Methods of transcriptionally modulating gene expression
DK0489149T3 (da) * 1990-06-27 2001-12-27 Univ Princeton Prober til påvisning af mutant P53
CA2094378A1 (en) * 1990-10-25 1992-04-26 Paul B. Fisher Development of dna probes and immunological reagents of human tumor associated antigens
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US6159751A (en) * 1990-10-25 2000-12-12 The Trustees Of Columbia University In The City Of New York Development of DNA probes and immunological reagents of human tumor associated antigens
WO1992013091A1 (en) * 1991-01-18 1992-08-06 Oncogene Science, Inc. Methods of transcriptionally modulating expression of oncogenes and tumor suppressor genes
US6110700A (en) * 1991-03-11 2000-08-29 The General Hospital Corporation PRAD1 cyclin and its cDNA
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
US5750335A (en) * 1992-04-24 1998-05-12 Massachusetts Institute Of Technology Screening for genetic variation
US5688918A (en) * 1993-08-02 1997-11-18 Health Research, Inc. p53as protein and antibody therefor
US5747650A (en) * 1993-08-02 1998-05-05 Health Research, Inc. P53AS protein and antibody therefor
US6965009B1 (en) 1993-08-02 2005-11-15 Health Research, Inc. p53 as protein and antibody therefor
US5726024A (en) * 1993-08-02 1998-03-10 Health Research, Inc. p53as protein and antibody therefor
AU1094795A (en) * 1993-11-12 1995-05-29 Oncor, Inc. Detection of bladder cancer
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US6524578B1 (en) 1996-07-10 2003-02-25 Scott E. Tackett Use of nuclease to reduce wrinkles and discolorations in humans
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5952178A (en) * 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
WO1998021585A1 (en) 1996-11-15 1998-05-22 Cornell Research Foundation, Inc. Activated ras interaction assay
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
AU752817B2 (en) 1999-02-25 2002-10-03 Exact Sciences Corporation Methods for preserving DNA integrity
EP1169479B1 (de) * 1999-04-09 2006-06-28 EXACT Sciences Corporation Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
CA2394921A1 (en) * 1999-12-07 2001-06-14 Anthony P. Shuber Supracolonic aerodigestive neoplasm detection
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005111244A2 (en) * 2004-05-10 2005-11-24 Exact Sciences Corporation Methods for detecting a mutant nucleic acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
WO2006026654A2 (en) 2004-08-27 2006-03-09 Exact Sciences Corporation Method for detecting a recombinant event
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
DE102005011022A1 (de) * 2005-03-10 2006-09-14 Häfner & Krullmann Gmbh Verfahren zum Bewickeln einer Spule mit strangförmigem Wickelgut
US9777314B2 (en) * 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
JP2009505658A (ja) * 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
JP2019517566A (ja) * 2016-06-10 2019-06-24 ライデン、ブロック 創傷パッキングを用いて創傷を治療するためのシステム及び方法
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299815A (en) * 1980-02-08 1981-11-10 Hoffmann-La Roche Inc. Carcinoembryonic antigen determination
US4368262A (en) * 1981-03-23 1983-01-11 Research Corporation Diagnostic test for the detection of cancer
US4395486A (en) * 1981-08-19 1983-07-26 Medical College Of Ga. Research Inst., Inc. Method for the direct analysis of sickle cell anemia

Also Published As

Publication number Publication date
DE3382767T2 (de) 1995-10-19
EP0239162A3 (en) 1989-08-16
ATE114820T1 (de) 1994-12-15
EP0241961B1 (de) 1994-11-30
DE3382767D1 (de) 1995-01-26
EP0239162B1 (de) 1994-12-14
WO1984001389A1 (en) 1984-04-12
ATE59412T1 (de) 1991-01-15
JPH0642840B2 (ja) 1994-06-08
DE3382765D1 (de) 1995-01-12
EP0120958B1 (de) 1990-12-27
EP0241961A2 (de) 1987-10-21
JPH05281228A (ja) 1993-10-29
DE3382098D1 (de) 1991-02-07
EP0239162A2 (de) 1987-09-30
EP0120958A1 (de) 1984-10-10
EP0241961A3 (en) 1989-01-25
JPS60500002A (ja) 1985-01-10
EP0605789A1 (de) 1994-07-13
JP2573770B2 (ja) 1997-01-22
US4786718A (en) 1988-11-22
US5300631A (en) 1994-04-05
US4535058A (en) 1985-08-13
DE3382765T2 (de) 1995-05-04

Similar Documents

Publication Publication Date Title
ATE115588T1 (de) Ein verfahren zur herstellung eines antikörpers, der zur bestimmung der anwesenheit eines menschlichen oncogens befähigt ist.
DE3381979D1 (de) Verfahren zur photometrischen bestimmung biologischer agglutinaten.
DE3678114D1 (de) Nichtzerstoerendes verfahren zur bestimmung des aushaertungsgrades eines polymers.
DE59405820D1 (de) Verfahren zur Ermittlung charakteristischer Eigenschaften von Radikale bildenden Prozessen
DE69022786D1 (de) Verfahren zur Bestimmung der Konzentration von Glucose.
DE3579119D1 (de) Verfahren zur bestimmung des oberflaechenglanzes eines koerpers.
DE68901541D1 (de) Verfahren zur herstellung von fluor enthaltenden olefinen.
DE68907783D1 (de) Verfahren zur herstellung von fluorierten aethern.
DE3689218D1 (de) Verfahren zur differenzierten Bestimmung weisser Blutkörperchen.
DE3682149D1 (de) Verfahren zur quantitativen bestimmung von 1,5-anhydroglucitol.
DE3853582D1 (de) Verfahren zur diagnose von leberkrebs oder leberzirrhose.
DE69026695D1 (de) Verfahren zur herstellung von hochfestem rostfreien bandstahl mit ausgezeichneten federeigenschaften
DE69121990D1 (de) Verfahren zur immunologischen Bestimmung des carboxyterminalen Peptids von Typ-I-Prokollagen
DE3776525D1 (de) Immunochemisches verfahren zur bestimmung von stabilem glykosiliertem haemoglobin.
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
ATE329265T1 (de) Verfahren zur instrumentellen bestimmung einer sich zeitabhängig ändernden messgrösse
AT383615B (de) Verfahren zur herstellung von hochchromhaeltigem stahl durch frischen
DE59009364D1 (de) Verfahren zur quantitativen Bestimmung zumindest eines chemischen Parameters eines Probenmediums.
DE68914252D1 (de) Verfahren zur Bestimmung eines Antigens.
DE3667960D1 (de) Verfahren zur herstellung von halogen-magnesium-alanat und dessen verwendung.
DE3671811D1 (de) Verfahren zur herstellung von halbleiteranordnungen mittels gasaetzen.
ATE153770T1 (de) Künstliche standard- und kontrollseren zur verwendung in verfahren zur bestimmung von antikörpern
DE59009773D1 (de) Verfahren zur Konzentrationsbestimmung mittels Atomabsorptions-Spektroskopie.
ATE64470T1 (de) Verfahren und zusammensetzungen zur bestimmung von heparin.
ATE7049T1 (de) Verfahren zur bestimmung der gammaglutamyltranspeptidase.